Risk factors for severe immune‐related pneumonitis after nivolumab plus ipilimumab therapy for non‐small cell lung cancer
Thoracic Cancer · 2024
DOI: 10.1111/1759-7714.15385 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thoracic Cancer, 2024. Verfasst von Toshiyuki Sumi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, Hakodate, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Nivolumab, Lung Neoplasms, Ipilimumab. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The efficacy of anti‐CTLA‐4 antibody (ipilimumab) plus anti‐programmed cell death 1 antibody (nivolumab) in treating advanced non‐small cell lung cancer (NSCLC) is impeded by an elevated risk of severe immune‐related adverse events. However, our understanding of associations among pre‐existing fibrosis, emphysematous changes, and objective indicators as predictive factors is limited for severe pneumonitis in NSCLC patients receiving this combination therapy. Thus, we retrospectively investigated these associations, including overall tumor burden, before treatment initiation in the Japanese population.
Methods
We focused on patients ( n = 76) with pre‐existing interstitial lung disease (ILD) to identify predictors of severe pneumonitis. Variables included age, sex, smoking status, programmed cell death ligand 1 expression, overall tumor burden, chest computed tomography‐confirmed fibrosis, serum markers, and respiratory function test results.
Results
Severe pneumonitis was more frequent in patients with squamous cell carcinoma, fibrosis, low diffusing capacity for carbon monoxide (%DLCO), and high surfactant protein D (SP‐D) level. Notably, squamous cell carcinoma, baseline %DLCO, and SP‐D level were significant risk factors. Our findings revealed the nonsignificance of tumor burden (≥85 mm) in predicting severe pneumonitis, emphasizing the importance of pre‐existing ILD. Conversely, in cases without pre‐existing fibrosis, severe pneumonitis was not associated with %DLCO or SP‐D level (93.2% vs. 91.9%, and 63.3 vs. 40.9 ng/mL, respectively) and was more common in patients with a large overall tumor burden (97.5 vs. 70.0 mm).
Conclusion
Vigilant monitoring and early intervention are crucial for patients with squamous cell carcinoma, high SP‐D level, or low %DLCO undergoing ipilimumab plus nivolumab therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, Hakodate Goryoukaku Hospital, Hakodate, Japan.
- Department of Respiratory Medicine and Allergology, Sapporo Medical University School of Medicine, Sapporo, Japan.
- Division of Radiology, Hakodate Goryoukaku Hospital, Hakodate, Japan.
ORCID-Profile: Toshiyuki Sumi, Naoki Shijubou
Zitieren
APA
Sumi, T., Sekikawa, M., Koshino, Y., Nagayama, D., Nagahisa, Y., Matsuura, K., Shijubou, N., Kamada, K., Suzuki, K., Ikeda, T., Michimata, H., Watanabe, H., Yamada, Y., Osuda, K., Tanaka, Y., & Chiba, H. (2024). Risk factors for severe immune‐related pneumonitis after nivolumab plus ipilimumab therapy for non‐small cell lung cancer. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15385
Vancouver
Sumi T, Sekikawa M, Koshino Y, Nagayama D, Nagahisa Y, Matsuura K, et al. Risk factors for severe immune‐related pneumonitis after nivolumab plus ipilimumab therapy for non‐small cell lung cancer. Thoracic Cancer. 2024. doi:10.1111/1759-7714.15385
BibTeX
@article{Sumi2024,
author = {Sumi, Toshiyuki and Sekikawa, Motoki and Koshino, Yuta and Nagayama, Daiki and Nagahisa, Yuta and Matsuura, Keigo and Shijubou, Naoki and Kamada, Koki and Suzuki, Keito and Ikeda, Takumi and Michimata, Haruhiko and Watanabe, Hiroki and Yamada, Yuichi and Osuda, Koichi and Tanaka, Yusuke and Chiba, Hirofumi},
title = {Risk factors for severe immune‐related pneumonitis after nivolumab plus ipilimumab therapy for non‐small cell lung cancer},
journal = {Thoracic Cancer},
year = {2024},
doi = {10.1111/1759-7714.15385}
}
EUVIMED